The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with ...

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Two former Pfizer executives published a statement saying they support the current company management as it gets pressured ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer (NYSE: PFE) ...